Literature DB >> 16752188

Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model.

W-Y Shen1, C M Lai, C E Graham, N Binz, Y K Y Lai, J Eade, D Guidolin, D Ribatti, S A Dunlop, P E Rakoczy.   

Abstract

AIMS/HYPOTHESIS: Vascular endothelial growth factor (VEGF) plays a pivotal role in the pathogenesis of diabetic retinopathy. We investigated whether transgenic mice with moderate VEGF expression in photoreceptors (trVEGF029) developed changes similar to diabetic retinopathy and whether retinopathy progressed with time.
MATERIALS AND METHODS: Human VEGF(165) (hVEGF(165)) expression was analysed using ELISA and quantitative RT-PCR; serum glucose levels were also measured. Fundus fluorescein angiography (FA) was used to screen the degree of retinopathy from 6 weeks. Dynamic changes in the density of retinal microvasculature, as well as other changes similar to diabetic retinopathy, including retinal leucostasis, capillary endothelial cell and pericyte loss, and numbers of acellular capillaries, were quantified.
RESULTS: trVEGF029 mice were normoglycaemic and showed a moderate, short-term hVEGF(165) upregulation for up to 3 weeks. Changes in the retinal microvasculature not only mimicked those seen in diabetic retinopathy, but also showed similar pathological progression with time. FA at 6 weeks identified two phenotypes, mild and moderate, which were distinguished by the extent of vascular leakage. Quantitative analysis of diabetic retinopathy-like changes revealed that these parameters were tightly correlated with the initial degree of vascular leakage; low levels reflected slow and limited retinal microvascular changes in mild cases and high levels reflected more rapid and extensive changes in moderate cases. CONCLUSIONS/
INTERPRETATION: The data suggest that even an early short-term elevation in hVEGF(165) expression might set a train of events that lead to progressive retinopathy. Induction of many features characteristic of diabetic retinopathy in trVEGF029 enables mechanisms leading to the disease state to be examined, and provides a relevant animal model for testing novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16752188     DOI: 10.1007/s00125-006-0274-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

1.  Studies of retinal vascular patterns. I. Normal architecture.

Authors:  T KUWABARA; D G COGAN
Journal:  Arch Ophthalmol       Date:  1960-12

2.  Generation of transgenic mice with mild and severe retinal neovascularisation.

Authors:  C-M Lai; S A Dunlop; L A May; M Gorbatov; M Brankov; W-Y Shen; N Binz; Y Ky Lai; C E Graham; C J Barry; I J Constable; L D Beazley; E P Rakoczy
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

3.  Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5.

Authors:  Guoquan Gao; Yan Li; Stephen Gee; Andrew Dudley; James Fant; Craig Crosson; Jian-xing Ma
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

4.  Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.

Authors:  R H Amin; R N Frank; A Kennedy; D Eliott; J E Puklin; G W Abrams
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

5.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition.

Authors:  K Miyamoto; S Khosrof; S E Bursell; R Rohan; T Murata; A C Clermont; L P Aiello; Y Ogura; A P Adamis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

Review 6.  Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes.

Authors:  José Cunha-Vaz; Rui Bernardes
Journal:  Prog Retin Eye Res       Date:  2004-12-16       Impact factor: 21.198

7.  Disappearance and formation rates of microaneurysms in early diabetic retinopathy.

Authors:  T Hellstedt; I Immonen
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

8.  Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy.

Authors: 
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-07       Impact factor: 4.799

9.  A central role for inflammation in the pathogenesis of diabetic retinopathy.

Authors:  Antonia M Joussen; Vassiliki Poulaki; Minh Ly Le; Kan Koizumi; Christina Esser; Hanna Janicki; Ulrich Schraermeyer; Norbert Kociok; Sascha Fauser; Bernd Kirchhof; Timothy S Kern; Anthony P Adamis
Journal:  FASEB J       Date:  2004-07-01       Impact factor: 5.191

10.  Central immunotolerance in transgenic mice expressing a foreign antigen under control of the rhodopsin promoter.

Authors:  Don-Il Ham; Stephen J Kim; Jun Chen; Barbara P Vistica; Robert N Fariss; Robert S Lee; Eric F Wawrousek; Hiroshi Takase; Cheng-Rong Yu; Charles E Egwuagu; Chi-Chao Chan; Igal Gery
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-03       Impact factor: 4.799

View more
  21 in total

1.  Characterization of a mouse model of hyperglycemia and retinal neovascularization.

Authors:  Elizabeth P Rakoczy; Ireni S Ali Rahman; Nicolette Binz; Cai-Rui Li; Nermina N Vagaja; Marisa de Pinho; Chooi-May Lai
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

2.  Reduction of experimental diabetic vascular leakage and pericyte apoptosis in mice by delivery of αA-crystallin with a recombinant adenovirus.

Authors:  Y H Kim; S Y Park; J Park; Y S Kim; E M Hwang; J Y Park; G S Roh; H J Kim; S S Kang; G J Cho; W S Choi
Journal:  Diabetologia       Date:  2012-07-08       Impact factor: 10.122

3.  Growth factor mediated assembly of cell receptor-responsive hydrogels.

Authors:  Nori Yamaguchi; Le Zhang; Byeong-Seok Chae; Chandra S Palla; Eric M Furst; Kristi L Kiick
Journal:  J Am Chem Soc       Date:  2007-02-22       Impact factor: 15.419

4.  Peptide- and protein-mediated assembly of heparinized hydrogels.

Authors:  Kristi L Kiick
Journal:  Soft Matter       Date:  2008-01-01       Impact factor: 3.679

5.  Progression of Diabetic Capillary Occlusion: A Model.

Authors:  Xiao Fu; John Scott Gens; James A Glazier; Stephen A Burns; Thomas J Gast
Journal:  PLoS Comput Biol       Date:  2016-06-14       Impact factor: 4.475

6.  Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome.

Authors:  Young Ree Kim; Seung-Ho Hong
Journal:  Biomed Rep       Date:  2015-02-04

7.  Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage.

Authors:  Juanjuan Wang; Xueliang Xu; Michael H Elliott; Meili Zhu; Yun-Zheng Le
Journal:  Diabetes       Date:  2010-06-08       Impact factor: 9.461

Review 8.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

Review 9.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

10.  Conditional Müllercell ablation causes independent neuronal and vascular pathologies in a novel transgenic model.

Authors:  Weiyong Shen; Marcus Fruttiger; Ling Zhu; Sook H Chung; Nigel L Barnett; Joshua K Kirk; SoRa Lee; Nathan J Coorey; Murray Killingsworth; Larry S Sherman; Mark C Gillies
Journal:  J Neurosci       Date:  2012-11-07       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.